TroyGould Attorneys Sign TroyGould Attorneys Sign

TroyGould Represents CytRx in $28 Million Public Offering of Common Stock

TroyGould PC represented long-time client CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, in connection with its underwritten public offering of 10,465,000 shares of common stock, for aggregate gross proceeds of approximately $28.8 million. The offering closed on July 24, 2015.

TroyGould members, Dale Short and Darren Freedman, handled the transaction.